Sotio

A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors

Retrieved on: 
Tuesday, June 27, 2023

SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member.

Key Points: 
  • Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member
    SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio , a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors.
  • "We are thrilled to welcome Heidi to our Board of Directors," said David Younger, CEO and Co-Founder of A-Alpha Bio.
  • Based in Seattle, Hagen will be on the ground to support and share her expertise and network with the A-Alpha Bio team.
  • "I am excited to join A-Alpha Bio's Board of Directors and collaborate with this dynamic team of biologists, protein engineers, and data scientists," said Hagen.

SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021

PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE) -- SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting.

Key Points: 
  • PRAGUE, Czech Republic, June 04, 2021 (GLOBE NEWSWIRE) -- SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting.
  • DCVAC/OvCa is being developed as a first line treatment in adults with ovarian cancer.
  • The data demonstrate signs of efficacy and safety of DCVAC/OvCa combined with chemotherapy in patients with newly diagnosed epithelial ovarian carcinoma and provide strong rationale for potential study in larger clinical trials.
  • Our data indicate a potentially strong effect of DCVAC/OvCa in patients with ovarian cancer, predominantly in patients with immunologically cold tumors, which showed to be refractory in clinical trials with immunotherapy so far.

SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting

Retrieved on: 
Tuesday, April 6, 2021

PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) -- SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting.

Key Points: 
  • PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) -- SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting.
  • The presentation focuses on preclinical data describing SOT102 which is intended for the treatment of CLDN18.2-expressing solid tumors.
  • SOT102 was studied in models of various CLDN18.2-positive solid tumors, mainly of gastric and pancreatic origin.
  • A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes.

SOTIO Presents Interim Data from its Phase 1/1b Study of SO-C101 in Patients with Advanced Solid Tumors at SITC 2020

Retrieved on: 
Wednesday, November 11, 2020

Two additional posters are also being presented highlighting the latest preclinical data on SO-C101.

Key Points: 
  • Two additional posters are also being presented highlighting the latest preclinical data on SO-C101.
  • We look forward to progressing in this study and demonstrating SO-C101 as safe a potential potent immunotherapy for patients with advanced solid tumors.
  • SOTIO presented two additional posters highlighting preclinical in vitro and in vivo SO-C101 pharmacokinetic, pharmacodynamic and mechanism of action data.
  • Cytune Pharma is responsible for the clinical development of SO-C101 and SOTIO is a sponsor of the Phase 1 clinical trial.

SOTIO to Present New Data on the IL-15 superagonist SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

Retrieved on: 
Wednesday, November 4, 2020

SO-C101 is an IL-15 superagonist currently being investigated in a Phase 1 trial for the treatment of advanced solid tumors.

Key Points: 
  • SO-C101 is an IL-15 superagonist currently being investigated in a Phase 1 trial for the treatment of advanced solid tumors.
  • Two additional posters will also be presented summarizing the latest preclinical data on SO-C101.
  • Date/ Time: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13 from 4:40-5:10 p.m. EST
    Date/ Time: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13 from 4:40-5:10 p.m. EST
    Selected presentation materials will be made available on the SOTIO website once the presentations conclude.
  • Cytune Pharma is responsible for the clinical development of SO-C101 and SOTIO is a sponsor of the Phase 1 clinical trial.

SOTIO to Present at BIO-Europe Digital 2020

Retrieved on: 
Monday, October 26, 2020

PRAGUE, Czech Republic, Oct. 26, 2020 (GLOBE NEWSWIRE) -- SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that Jens Hennecke, chief business officer of SOTIO, is presenting at BIO-Europe Digital being held on October 26-29, 2020.

Key Points: 
  • PRAGUE, Czech Republic, Oct. 26, 2020 (GLOBE NEWSWIRE) -- SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced that Jens Hennecke, chief business officer of SOTIO, is presenting at BIO-Europe Digital being held on October 26-29, 2020.
  • The presentation will be made available on demand on the Bio Europe website and accessible to attendees registered for the event.
  • The 26th annual BIO-Europe global life sciences partnering event is being held on October 2629 in a fully digital format.
  • The event is expected to bring together over 3,000 executives from more than 1,400 life sciences companies spanning an estimated 50+ countries.

Unum Therapeutics Transfers BOXR Cell-Based Therapy Technology to SOTIO

Retrieved on: 
Monday, August 31, 2020

The sale to SOTIO will enable it to further advance its goal to develop the next generation of potent immunotherapies for patients with cancer.

Key Points: 
  • The sale to SOTIO will enable it to further advance its goal to develop the next generation of potent immunotherapies for patients with cancer.
  • Unum will retain its antibody coupled T cell receptor (ACTR) technology and continues to explore strategic opportunities for the technology and assets.
  • "We are extremely proud of the BOXR technology and programs and would like to thank all of our employees, and investors for not only supporting our vision, but advancing it as well.
  • SOTIO will assume responsibility for a portion of Unum's facilities in Cambridge, MA to advance the BOXR programs, and certain Unum staff associated with the BOXR programs will transition to SOTIO to continue their work on the programs.

SOTIO Acquires Rights to BOXR CAR-T Platform and Products from Unum Therapeutics

Retrieved on: 
Monday, August 31, 2020

The proprietary Bolt-on Chimeric Receptor technology incorporates novel transgenes to enhance T cell function in the solid tumor microenvironment.

Key Points: 
  • The proprietary Bolt-on Chimeric Receptor technology incorporates novel transgenes to enhance T cell function in the solid tumor microenvironment.
  • SOTIO aims to develop multiple enhanced Chimeric Antigen Receptor (CAR)-T cell therapies for the treatment of solid tumors based on the BOXR technology.
  • In addition to acquiring the BOXR platform, several of Unums experienced research team members who were responsible for the research and development of the BOXR technology, including Geoff Hodge, former chief technology officer of Unum, will be joining SOTIO to continue advancing the BOXR R&D programs.
  • SOTIO has assembled a seasoned and talented development team, including experienced Unum team members, and we look forward to SOTIOs progress on the BOXR programs in the future.

SOTIO to Present at the LifeSci Partners Summer Symposium

Retrieved on: 
Thursday, July 30, 2020

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.

Key Points: 
  • SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
  • SOTIOs robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies and a new generation of potent and stable antibody-drug conjugates (ADCs).
  • SOTIO is a member of the PPF Group.
  • SOTIO is a registered trademark of SOTIO a.s. in selected countries.

SOTIO Announces First Patient Dosed in Part B of Phase 1/1b Study with SO-C101 in Combination with Pembrolizumab in Patients with Solid Tumors

Retrieved on: 
Tuesday, July 14, 2020

Part B will examine SO-C101 in combination with PD-1 inhibitor pembrolizumab.

Key Points: 
  • Part B will examine SO-C101 in combination with PD-1 inhibitor pembrolizumab.
  • Part B now allows for the pembrolizumab combination phase of this dose-escalation study to progress.
  • The ongoing multicenter, open-label Phase 1/1b study, SC103 ( NCT04234113 ), is evaluating the safety and preliminary efficacy of SO-C101 as monotherapy (Part A) and in combination with pembrolizumab (Part B) in patients with selected relapsed/refractory advanced/metastatic solid tumors.
  • Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is a sponsor of the Phase 1 clinical trial.